Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study

Phase

Condition

Claudication

Venous Thrombosis

Thrombosis

Treatment

N/A

Clinical Study ID

NCT02627053

RIVASVT-100

Ages 18-100
All Genders

Study Summary

Anticoagulant therapy is generally recommended for all patients presenting with acute symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin (LMWH) or unfractionated heparin and continuing with the vitamin K antagonists in most patients. Rivaroxaban is approved for the treatment of deep vein thrombosis and pulmonary embolism, but no studies have assessed the safety of rivaroxaban in the setting of splanchnic vein thrombosis. The investigators aim to collect prospective information on the safety of rivaroxaban in a pilot cohort of 100 patients with acute splanchnic vein thrombosis without liver cirrhosis.

Eligibility Criteria

Inclusion

Inclusion criteria:

Consecutive patients aged 18 years or older
first episode of symptomatic, objectively diagnosed PVT, MVT, or spVT
signed informed consent.

Exclusion

Exclusion criteria:

known liver cirrhosis (biopsy proven or with clinical, laboratory, or imaging evidenceof chronic liver disease, within a context of chronic alcoholism, viral hepatitis,autoimmunity, Wilson's disease, iron overload)
alanine aminotransferase level that is three times the upper limit of the normal rangeor higher
Budd-Chiari syndrome
previous or ongoing vatical bleeding
presence of portal vein cavernoma at the time of diagnosis
anticipated abdominal surgical procedure
known bleeding diathesis
platelet count <100.000 mm3
creatinine clearance <30 mL/min (Cockroft-Gault formula)
life expectancy of less than 3 months
expected inability to take oral medications
concomitant treatment with azole antimycotics and human immunodeficiency virusprotease inhibitors - treatment with therapeutic doses of LMWH or UFH for more than 7days
ongoing treatment with VKA
pregnancy or lactation

Study Design

December 01, 2015

December 31, 2019

Study Description

Patients with splanchnic vein thrombosis are at increased risk of recurrent VTE and bleeding. Routine anticoagulation with unfractionated heparin or low molecular weight heparin followed by warfarin is recommended in this setting, but limited data is available to support this recommendation and more than 20% of these patients do not receive antithrombotic treatment due the fear for bleeding complications. The pharmacokinetic and pharmacodynamic characteristics of rivaroxaban make this drug an ideal alternative therapeutic strategy for the treatment of patients with SVT. Thanks to the oral route of administration, the short half-life, the high bioavailability, the predictable dose-response and the lack of effects on platelet activity, rivaroxaban could result as an important alternative to both LMWH and warfarin in the acute and long-term treatment of SVT patients. Furthermore, the analysis of phase III studies conducted in patients with DVT or PE have shown a better safety profile of rivaroxaban as compared to standard of treatment. This observed benefit in the safety profile of rivaroxaban would be extremely relevant in the treatment of patients with SVT. In this prospective cohort study, patients presenting with acute SVT will receive rivaroxaban 15 mg bid for 3 weeks followed by rivaroxaban 20 mg od for a total of 3 months. The primary safety and efficacy outcomes will be measured at 3 months.

Connect with a study center

McMaster University
Hamilton,
Canada
Active - Recruiting
University of Western Ontario
London,
Canada
Active - Recruiting
University of Ottawa
Ottawa,
Canada
Active - Recruiting
Ospedale di Circolo
Varese, 21100
Italy
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.